Emcure Pharmaceuticals announced a robust 20% YoY revenue growth, reaching ₹2,363Cr in Q3FY26. EBITDA stood at ₹460Cr, up 27.2% YoY, with margins at 19.5%. Profit After Tax (PAT) increased by 48.2% YoY to ₹231Cr. The company launched Poviztra®, a biological injectable form of semaglutide, strengthening its position in the weight management segment. Domestic sales grew by 15.4%, while international sales increased by 24.5%.
Financial Performance
Emcure Pharmaceuticals reported strong financial results for Q3FY26:
- Revenue from operations: ₹2,363Cr, a 20.4% increase year-over-year.
- EBITDA: ₹460Cr, reflecting a 27.2% YoY growth, with margins at 19.5%.
- Profit After Tax (PAT): ₹231Cr, demonstrating a substantial 48.2% YoY increase.
The quarter’s PAT includes an exceptional expense of ₹38Cr related to labour code changes.
Segment Performance
Both domestic and international businesses contributed to the company’s strong performance:
- Domestic Business: Sales reached ₹1,025Cr, a 15.4% YoY increase.
- International Business: Sales totaled ₹1,338Cr, reflecting a 24.5% YoY growth.
Specifically, the Rest of the World (RoW) business grew by 30.7%, driven by strong performances in both non-ARV and ARV segments. Europe saw continued traction, and the Canadian business experienced robust growth of 12.8%.
Strategic Launch
Emcure launched Poviztra®, a biological injectable form of semaglutide, in India during the quarter. This launch, in partnership with Novo Nordisk, positions Emcure as a key player in the fast-growing weight management segment.
Source: BSE
